Companies › CytoCares
1 active drug program in 2 registered trials: 2 Phase 1; Immunology, Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CC312 anti-CD19 monoclonal antibody | CD19 | Phase 1 | Non-hodgkin Lymphoma; SLE - Systemic Lupus Erythematosus | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06037018 | CC312 | Phase 1 | Non-hodgkin Lymphoma | Oncology | Mar 2026 |
| NCT07177911 | CC312 | Phase 1 | SLE - Systemic Lupus Erythematosus | Immunology | Sep 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.